Febhuwari 2022: E-China, isiguli ukuphila kwaso kwase kuseduze nokuphela kwelashwe ngokuphelele ngenxa ye-leukemia Ukwelashwa kwe-CAR T-cell, okwashukumisa isimiso somzimba sokuzivikela ezifweni. Wonke amangqamuzana omdlavuza ashabalala ngokushesha ocwaningweni lokuqala lohlobo lwawo. Ukwelashwa kwe-immune-mediated, eyasungulwa e-United States ngososayensi be-ACGT abafana noDkt. Carl June wase-University of Pennsylvania kanye noDkt. Michel Sadelain we-Memorial-Sloan Kettering Cancer Center, phakathi kokunye, kuphumelela ngokushesha kakhulu ukuhlolwa kwabantu nezinkulungwane zeziguli.
Ngemva kokwelashwa nge-CAR T-cell, owesifazane oseminyakeni ephakathi kubikwa ukuthi welashwa i-leukemia. “Amangqamuzana omdlavuza emzimbeni wakhe anyamalele. USolwazi Qian Cheng, umqondisi weBio-Treatment Centre esibhedlela eChongqing, uthe, "Uyisiguli sokuqala eseselapheka ngokuphelele kulesi simo ngokwelashwa ngofuzo."
I-leukemia itholakale cishe kubantu abayizigidi ezine eChina. Ukwelashwa kwe-CAR T iwukwelapha ngofuzo esebenzisa amaseli e-T ashintshiwe ukulwa namaseli omdlavuza ezigulini ze-leukemia. Iziguli eziningi zelashwa nge-chemotherapy noma ukufakelwa komnkantsha. “Ukwelashwa kwe-CAR T kungenye indlela engcono kakhulu,” kusho uProfesa Qian, “njengoba inganciphisa izindleko okungenani ngo-30% uma iqhathaniswa nokufakelwa komnkantsha wamathambo futhi cishe ingase iholele ekwelapheni.”
NgokukaSolwazi uQian, ezinye iziguli eziyisithupha ezithola ukwelashwa ngofuzo esikhungweni esisodwa seziyithuthukisile impilo yazo. E-China, ukwelashwa ngofuzo lwe-CAR T kusesesigabeni sokuhlolwa komtholampilo, njengoba kunezibhedlela eziyishumi kuphela ezikutholile ezweni lonke. Impumelelo ikhuthaze ithimba lika-Qian, elizoqhubeka nokucwaninga imithamo ukuze kuthuthukiswe umuthi wenoveli.